SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): January 16, 2015
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
(State or Other Jurisdiction
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
Registrant’s telephone number,
including area code: (212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
James M. Turner, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|o||Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|o||Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|o||Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 16, 2015,
Tonix Pharmaceuticals Holding Corp. (the “Company”) notified Donald Kellerman, the Company’s Senior Vice President
Clinical Development and Regulatory Affairs, that the Company would not renew Dr. Kellerman’s employment agreement upon its
expiration on March 31, 2015 and that his employment would terminate upon expiration of his employment agreement.
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
||TONIX PHARMACEUTICALS HOLDING CORP.|
|Date: January 16, 2015
||By: /s/ LELAND GERSHELL|
||Chief Financial Officer|